To develop its drugs quickly and at a relatively low cost, Regeneron uses a proprietary process in which they insert human DNA into mice, according to Forbes. Good morning.

But yes, the president’s case is a case report, perhaps the most analyzed case report ever,–.

The following is a transcript of an interview with Regeneron CEO Leonard Schleifer that aired Sunday, October 11, 2020, on "Face the Nation."MARGARET.

After starting Regeneron in 1988 with co-founder Dr. George Yancopoulos, the company has grown from a small startup to a leader in biotechnology. But Schleifer is more than just the man that supplies Trump’s experimental drug treatment — he has known the president for years and is a member of the Trump National Golf Club in Westchester. MARGARET BRENNAN: But your drug, does it create immunity? The treatment, which is called a monoclonal antibody cocktail, works in a vaccine-like way, aiming to boost an individual’s immune defenses before more severe symptoms take root. SCHLEIFER:– while we’re building this plane and flying it at the same time to be ready to answer some of those questions as well. SCHLEIFER: Right. With the help of $500 million in federal funding, Regeneron is developing an experimental drug to combat COVID-19 in those that have already been infected using an "antibody cocktail," per The New York Times. AstraZeneca is involved. I’m just saying we as- as a society. Schleifer proceeded to recruit advisors and a board of directors for his new venture, one of whom introduced him to Yancopoulos, per Forbes. The company sold $4.6 billion worth of that drug in 2019 alone, Forbes reported. But the real evidence has to come about how good a drug is and what it will do on average has to come from these large clinical trials, these randomized clinical trials, which are the gold standard. "I am a product of my environment who became the obsessive-compulsive science guy.". "His father wanted to interview me, rather than me convincing George," Schleifer told Forbes in 2013. And those are ongoing. (https://cornellsun.com/2020/10/08/regeneron-ceo-leonard-schleifer-73-involved-in-trump-experimental-covid-19-treatment/), Regeneron CEO Leonard Schleifer ’73 brought the biotech company from a start-up to a "powerhouse.". We need the entire industry. We- maybe we can treat the other people in the nursing home.

"Varsity Blues" college admissions scandal, coronavirus business & economic impact analysis, How electric truck startup founder Thomas Healy went from teen racer to self-made billionaire and youngest CEO of a publicly traded company, 5 tax breaks Trump took advantage of that the average American can't. When the virus comes in your system, your immune system is trying to create immunity. SCHLEIFER: Could be months, could be years. Since the drug is still in experimental stages, it’s not available to the general public through any means other than a clinical trial. Subscriber Both of their fortunes largely stem from their stakes in Regeneron. Schleifer has an estimated net worth of $2.5 billion.

We all have to step up–. Schleifer spends most of his time in the affluent New York suburb of Chappaqua, but also owns a 15-acre estate in Martha's Vineyard, Curbed reported. Look, we need- Regeneron can’t do this alone. The son of Greek immigrants who had been refugees in Turkey, Yancopoulos excelled at science from an early age, Forbes reported. SCHLEIFER: A vaccine- well, it depends on how you acquire this immunity. And there were shortages of that, which is why I ask you. Even before he took the drug, the president was friendly with Schleifer. And we have to get the entire–. Amgen is involved. The news of Regeneron's promising COVID-19 treatment sent its stock price up more than 60% in 2020 so far. But the Trump administration last year has suspended federal funding for research projects that involve fetal tissue from abortions. Coming up with a distribution system where we take what’s limited, and we try and give it to the people who most need it, who would most benefit from it. The Cornell Daily Sun Sign up for Insider Life. Although, there are some very interesting aspects of his case, such as he was elderly, he had some risk factors, and that he did not have his own immune system in gear when he was sick and he got treated with our immune system in a vial, if you will. There are also vaccine makers using the cell line.

Sunday, October 11 2020 . Both Regeneron and the FDA approved the president's request to take the drug, and he was given the higher of the two doses currently being studied.

It didn't hurt that Schleifer and Yancopoulos' partnership had parental approval from the get-go. "All we can say is that they asked to be able to use it, and we were happy to oblige," Schleifer told The Times Friday. In some cases, vaccines can last for decades.

REGENERON CEO LEONARD SCHLEIFER: Good morning, MARGARET.

Regeneron and CEO Leonard Schleifer ’73 have gained recognition for the experimental drug cocktail that has shown promising results in treating the initial symptoms of COVID-19 infections. NFL Postpones Broncos-Patriots Game Indefinitely | Sports News, Portland Thorns clinch NWSL Fall Series Community Shield with victory over OL Reign, “Cheer” star Jerry Harris asks for jail release until trial, Qatar Investment Authority bets big on private and public equity: CEO, California elections officials order Republicans to remove illegal ballot drop boxes, US poll results, economic recovery could shape outcome of LAC row | India News, Dr. Fauci says his kids aren’t coming home for Thanksgiving to stay safe from coronavirus. Do you have a personal experience with the coronavirus you'd like to share? MARGARET BRENNAN: Well, and exactly that point, providing enough is a key question. SCHLEIFER: I think in consultation with local health authorities, that’s what they’ve been doing with remdesivir, Gilead’s drug. Despite his accomplishments, Yancopoulos told Westchester Magazine that when people first meet him they think: "That guy is supposed to be smart? MARGARET BRENNAN: Understood. Schleifer told The Times that other COVID-19 patients had been approved to take the drug as well. SCHLEIFER: It’s just- so let’s not- we shouldn’t exaggerate the situation. That’s an experimental treatment that has been received by only 10 other people outside of ongoing … Thank you, Doctor, for your time.

CEO Leonard Schleifer told CBS' "Face the …

MARGARET BRENNAN: That’s not even enough. He is divorced and lives in Yorktown Heights, New York, per Forbes. What I think that the administration has been working recently- I saw an announcement with- with AstraZeneca.

Yancopoulos also told The Times that the company is expecting a wave of new requests for the drug from sick patients following the president's usage of it, but a Regeneron spokesperson said that "our first priority is to maintain a sufficient supply in order to conduct rigorous clinical trials.". By clicking ‘Sign up’, you agree to receive marketing emails from Business Insider The president has also said he wants to make your drug free to anyone who needs it. Regeneron has also worked on treatments for Ebola and MERS, endeavors that helped prepare the company for its work on the coronavirus, Business Insider's Andrew Dunn reported. SCHLEIFER: Yeah. Read more: Trump just received Regeneron's experimental COVID-19 treatment.

There were nearly 60,000 people infected in this country on Friday alone, just on Friday. He's an inventor and a scientist?". The CEO met with Trump and his coronavirus task force in early March. I want to ask you something specific to how your drug was developed. ", "This is certainly putting us in a difficult situation ... We didn't want to decide who gets a limited number of doses," Yancopoulos told The New York Times about the president's request for early access to the drug. Now, Regeneron has not only gained recognition for its success, but also the experimental drug cocktail that has shown promising results in treating the initial symptoms of COVID-19 infections. "When it's the president of the United States, of course, that gets — obviously — gets our attention. Regeneron has produced six different drugs with this process, including its biggest moneymaker, vision loss treatment Eylea. But regardless of the success and press that Schleifer has received as Regeneron’s CEO, during times of crisis, the health of patients is at the forefront. We’ve got some preliminary evidence that we’ve talked with the FDA, and we’re going for an emergency use authorization, because we think it’s appropriate at this time. But what are antibodies, and how can they be repurposed into drugs to help people recover from COVID-19? Is it a prophylactic? He was the valedictorian of his class at New York's elite Bronx High School of Science and was a semifinalist in a national high-school science competition, The Wall Street Journal reported. Although the drug has yet to be approved by the FDA for use in emergency situations, President Trump was able to gain access to it through a special provision called "compassionate use" that allows patients to take drugs still going through trials when no other treatment is available. They met because Schleifer is a member at the Trump National Golf Club in Westchester County, near Regeneron's headquarters. Get the latest coronavirus business & economic impact analysis from Business Insider Intelligence on how COVID-19 is affecting industries. We’re partners with Roche, one of the best companies in this whole field.

So stay with us. We have companies like Lilly, great companies.

Help keep us reporting with a tax-deductible donation to the Cornell Daily Sun Alumni Association, a non-profit dedicated to aiding The Sun.